brivaracetam / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 24 Diseases   12 Trials   12 Trials   871 News 


«12345678910111213»
  • ||||||||||  brivaracetam / Generic mfg.
    A Modern Artillery to put off the Electric Storm of the Brain (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_2890;    
    While there are no high-quality studies substantiating the efficacy of brivaracetam as a first-line medication, its pharmacokinetic/pharmacodynamic properties could make it a reasonable alternative to benzodiazepines as the first-line anti seizures medication, especially in pre-existing tenuous airways to avoid further compromise and reduce ICU and hospital length of stay. The benefits of its fast onset of action and efficacy may mitigate the major barriers of ready accessibility and cost.
  • ||||||||||  Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
    Long-term Cenobamate for Uncontrolled Focal Seizures in Patients Living in a Group Home or With Developmental Disability (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_1887;    
    Dose reductions were most common with lacosamide (n=12; median reduction, 50%), brivaracetam (n=4, 50%), clobazam (n=4; 80%), lamotrigine (n=3; 50%), and perampanel (n=3; all 100%). Conclusions Patients living in a group home or with developmental disability achieved substantial reduction in seizure frequency at 12 months with adjunctive cenobamate.
  • ||||||||||  Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
    Retention of Cenobamate in the Real World (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_1886;    
    Conclusions Cenobamate was associated with significantly better retention vs 4 pooled branded ASMs in this analysis of real-world use. Unmeasured differences across the 2 groups that impact differential retention outcomes (eg, patient severity, drug load, and use of monotherapy) are potential limitations of this analysis.
  • ||||||||||  Review, Journal:  Epilepsy and brain tumors: Two sides of the same coin. (Pubmed Central) -  Mar 7, 2023   
    Future trials with a prospective, randomized, and controlled design accounting for different prognostic factors will help clarify the role of these ASMs and the clinical setting in which they might be used. In conclusion, brain tumor-related epilepsies are clear examples of how close, multidisciplinary collaborations among investigators with different expertise are warranted for pursuing scientific knowledge and, more importantly, for the well-being of patients needing targeted and effective therapies.
  • ||||||||||  Nuplazid (pimavanserin) / Acadia Pharma
    Journal:  Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies. (Pubmed Central) -  Mar 3, 2023   
    Propensity score non-overlap should be reported in comparative studies that include newer medications. When studies comparing newer and established treatments are critically needed as soon as new treatments enter the market, investigators should recognize the potential for channeling bias and implement methodological approaches like those demonstrated in this study to understand and improve this issue in such studies.
  • ||||||||||  brivaracetam / Generic mfg.
    Enrollment open:  Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (clinicaltrials.gov) -  Feb 14, 2023   
    P3,  N=40, Recruiting, 
    When studies comparing newer and established treatments are critically needed as soon as new treatments enter the market, investigators should recognize the potential for channeling bias and implement methodological approaches like those demonstrated in this study to understand and improve this issue in such studies. Not yet recruiting --> Recruiting
  • ||||||||||  brivaracetam / Generic mfg.
    Journal:  Brivaracetam to Treat Partial Onset Seizures in Adults. (Pubmed Central) -  Feb 3, 2023   
    There are approximately 30 antiepileptic agents for clinicians to choose from. Brivaracetam is a novel antiepileptic agent that was approved for use by the FDA in 2016 and is showing promising results as monotherapy and adjunctive therapy in individuals with drug-refractory focal seizures while minimizing adverse drug reactions.
  • ||||||||||  brivaracetam / Generic mfg.
    Trial completion date, Trial primary completion date:  An Open Label, Balanced, Randomized, 3 (clinicaltrials.gov) -  Feb 1, 2023   
    P1,  N=12, Active, not recruiting, 
    Brivaracetam is a novel antiepileptic agent that was approved for use by the FDA in 2016 and is showing promising results as monotherapy and adjunctive therapy in individuals with drug-refractory focal seizures while minimizing adverse drug reactions. Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
  • ||||||||||  brivaracetam / Generic mfg.
    Review, Journal:  A review of cognitive and behavioral outcomes of Brivaracetam. (Pubmed Central) -  Jan 21, 2023   
    For patients who are intolerant to levetiracetam and have levetiracetam-related behavioral side effects, switching to BRV could be beneficial. However, heterogeneity between studies resulted in low-quality of evidence, and further trials are needed to confirm the findings.
  • ||||||||||  brivaracetam / Generic mfg.
    Trial completion date:  Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study (clinicaltrials.gov) -  Jan 19, 2023   
    P=N/A,  N=200, Active, not recruiting, 
    However, heterogeneity between studies resulted in low-quality of evidence, and further trials are needed to confirm the findings. Trial completion date: Feb 2023 --> Jul 2023
  • ||||||||||  Fycompa (perampanel) / Eisai, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
    Review, Journal:  New evidence in adjunctive treatment of focal-onset seizures in adults: a critical appraisal. (Pubmed Central) -  Jan 12, 2023   
    Although network meta-analyses are not substitutes of direct comparisons, they can provide valuable evidence about the hierarchy of interventions. Additional real-world data can be useful complement to characterize the clinical profile and therapeutic potentialities of third-generation ASMs.
  • ||||||||||  brivaracetam / Generic mfg.
    Enrollment closed:  Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury (clinicaltrials.gov) -  Dec 22, 2022   
    P1/2,  N=24, Active, not recruiting, 
    ASD -induced reversal of synaptic and cognitive deficits would provide evidence that epileptic activity plays a causal role in ?S -dependent pathology. Recruiting --> Active, not recruiting
  • ||||||||||  levetiracetam / Generic mfg., brivaracetam / Generic mfg.
    Journal:  Brivaracetam or levetiracetam in status epilepticus?: Lessons from the photosensitivity model. (Pubmed Central) -  Dec 18, 2022   
    This modified design allows one to monitor the time to CNS effect (i.e., PPR elimination) of a quickly-acting FDA-approved ASM given i.v., a crucial element in status epilepticus treatment. This paper was presented at the 8th London-Innsbruck Colloqium on Status Epilepticus and Acute Seizures held in September 2022.
  • ||||||||||  Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
    Long-term Effect of Cenobamate in a Cohort of Therapy Refractory Adult Patients with Different Types of Epilepsies (Hall B, Level 3) -  Nov 29, 2022 - Abstract #AES2022AES_1344;    
    The comedication was lamotrigine (49), valproate (41), clobazam (35), brivaracetam/levetiracetam (37), lacosamide (15), oxcarbazepine (15), perampanel (7), zonisamide (5), stiripentol (5), topiramate (4), phenobarbital (2), rufinamide (1), felbamate (1), carbamazepine (1). Overall, adjunct CNB has been found to be generally safe and effective for treatment-resistant seizures in adult pts, a few therapy-resistant pts got seizure free and the retention rate, a mixture of effect and side effects was 91.4% after 6 months.
  • ||||||||||  lacosamide / Generic mfg.
    Outcomes of Patients on Lacosamide Medication During Pregnancy (Hall B, Level 3) -  Nov 29, 2022 - Abstract #AES2022AES_1102;    
    Additionally, DNCs exhibited a decreasing trend during pregnancy, confirming that regular, optimized LCM dosage changes may be necessary to achieve the best possible maternal and fetal outcomes. Future analyses in larger cohort sizes are needed.
  • ||||||||||  Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
    Retention of Cenobamate in the Real World (Hall B, Level 3) -  Nov 29, 2022 - Abstract #AES2022AES_1065;    
    Cenobamate was associated with significantly better retention vs. a pooling of four branded ASMs in this analysis of real-world use. A limitation of this analysis is the potential for unmeasured differences across the two groups that impact differential retention outcomes such as patient severity, drug load, and use of monotherapy.